Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
It is developing the drug candidate to potentially treat immunological diseases
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
Subscribe To Our Newsletter & Stay Updated
